Skip to Content

Blincyto Approval History

FDA Approved: Yes (First approved December 3, 2014)
Brand name: Blincyto
Generic name: blinatumomab
Dosage form: Injection
Company: Amgen Inc.
Treatment for: Acute Lymphoblastic Leukemia

Blincyto (blinatumomab) is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), and minimal residual disease (MRD)-positive B-cell precursor ALL.

Development History and FDA Approval Process for Blincyto

DateArticle
Mar 29, 2018Approval FDA Expands Approval of Blincyto (blinatumomab) to Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
Jul 11, 2017Approval FDA Grants Full Approval for Blincyto (blinatumomab) to Treat Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Adults and Children
Sep  1, 2016Approval FDA Approves Blincyto (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
Dec  3, 2014Approval FDA Approves Blincyto (blinatumomab) for Precursor B-Cell Acute Lymphoblastic Leukemia
Oct  9, 2014Amgen's BiTEĀ® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia
Sep 22, 2014Amgen Submits BLA for Investigational BiTEĀ® Immunotherapy Blinatumomab
Jul  1, 2014Amgen Receives FDA Breakthrough Therapy Designation For Investigational BiTE Antibody Blinatumomab In Acute Lymphoblastic Leukemia

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide